These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Sevoflurane selectively increases coronary collateral blood flow independent of KATP channels in vivo. Kersten JR; Schmeling T; Tessmer J; Hettrick DA; Pagel PS; Warltier DC Anesthesiology; 1999 Jan; 90(1):246-56. PubMed ID: 9915334 [TBL] [Abstract][Full Text] [Related]
24. Sympathetic influences on the native canine coronary collateral circulation. Euler DE Cardiovasc Res; 1995 Jan; 29(1):33-7. PubMed ID: 7895236 [TBL] [Abstract][Full Text] [Related]
25. Reduction in blood flow in normal and narrowed coronary arteries of dogs by leukotriene C4. Wargovich T; Mehta J; Nichols WW; Pepine CJ; Conti CR J Am Coll Cardiol; 1985 Nov; 6(5):1047-51. PubMed ID: 4045029 [TBL] [Abstract][Full Text] [Related]
26. Alterations in collateral blood flow produced by isoflurane in a chronically instrumented canine model of multivessel coronary artery disease. Hartman JC; Kampine JP; Schmeling WT; Warltier DC Anesthesiology; 1991 Jan; 74(1):120-33. PubMed ID: 1986637 [TBL] [Abstract][Full Text] [Related]
33. Nitric oxide inhibition impairs blood flow during exercise in hearts with a collateral-dependent myocardial region. Traverse JH; Kinn JW; Klassen C; Duncker DJ; Bache RJ J Am Coll Cardiol; 1998 Jan; 31(1):67-74. PubMed ID: 9426020 [TBL] [Abstract][Full Text] [Related]
34. Creation of anastomoses between an extracardiac artery and the coronary circulation. Proof that myocardial angiogenesis occurs and can provide nutritional blood flow to the myocardium. Unger EF; Sheffield CD; Epstein SE Circulation; 1990 Oct; 82(4):1449-66. PubMed ID: 1698130 [TBL] [Abstract][Full Text] [Related]
35. Effects of nicorandil, a new antianginal agent, and nifedipine on collateral blood flow in a chronic coronary occlusion model. Lamping KA; Warltier DC; Hardman HF; Gross GJ J Pharmacol Exp Ther; 1984 May; 229(2):359-63. PubMed ID: 6232374 [TBL] [Abstract][Full Text] [Related]
36. Protamine inhibits coronary collateral development in a canine model of repetitive coronary occlusion. Kersten JR; Pagel PS; Warltier DC Am J Physiol; 1995 Feb; 268(2 Pt 2):H720-8. PubMed ID: 7532374 [TBL] [Abstract][Full Text] [Related]
37. The cardioprotective effects of the thromboxane receptor antagonist SQ 30,741 are not reversed by aspirin. Grover GJ; Parham CS; Schumacher WA Basic Res Cardiol; 1991; 86(2):99-106. PubMed ID: 1831610 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs. Tanabe M; Terashita Z; Nishikawa K; Hirata M J Cardiovasc Pharmacol; 1984; 6(3):442-8. PubMed ID: 6202970 [TBL] [Abstract][Full Text] [Related]
39. Effect of beta-adrenergic receptor blockade on blood flow to collateral-dependent myocardium during exercise. Traverse JH; Altman JD; Kinn J; Duncker DJ; Bache RJ Circulation; 1995 Mar; 91(5):1560-7. PubMed ID: 7867199 [TBL] [Abstract][Full Text] [Related]
40. Neuropeptide Y and coronary vasoconstriction: role of thromboxane A2. Martin SE; Kuvin JT; Offenbacher S; Odle BM; Patterson RE Am J Physiol; 1992 Oct; 263(4 Pt 2):H1045-53. PubMed ID: 1415751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]